Blood Compatibility Characteristics of Baxter Xenium+, Fresenius FX and Gambro Polyflux Dialyzers
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of the dialyzer evaluation is to compare performance characteristics and haemocompatibility of the Baxter Xenium+ (Polynephron), Fresenius FX and Gambro Polyflux dialyzers
| Condition |
|---|
|
End Stage Renal Failure on Dialysis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Crossover Time Perspective: Prospective |
| Official Title: | Post Marketing Surveillance Investigating Blood Compatibility Characteristics of Baxter Xenium+, Fresenius FX and Gambro Polyflux Dialyzers |
- Clearance for urea, phosphate, beta-2-microglobulin blood cell drop, complement factor C5a, TAT [ Time Frame: January 2011 ] [ Designated as safety issue: Yes ]
- General survey of the dialysis treatments [ Time Frame: January 2011 ] [ Designated as safety issue: Yes ]Registration of adverse effects of the dialysis treatments
| Enrollment: | 8 |
| Study Start Date: | December 2010 |
| Study Completion Date: | February 2011 |
| Primary Completion Date: | January 2011 (Final data collection date for primary outcome measure) |
The Xenium+ is a new high flux dialyzer made from Polynephron membrane designed and manufactured by the Nipro Company in Japan. This dialyzer has been subjected to in-vitro testing, and all legally required biological safety tests have been conducted and CE-mark was granted in June 2010. Xenium+ has the same Polynephron membrane as the Xenium family of dialyzers which has been available commercially globally for approximately three years. Clinical evaluations have been completed with the Polynephron membrane within the last three years. The improvement in the Xenium+ line is that the casing is now made from polypropylene.
The aim of the dialyzer evaluation is to compare performance characteristics and hemocompatibility of the Xenium+ (Polynephron), Fresenius FX and Gambro Polyflux dialyzers.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
8 patients will undergo 1 treatment each with the 4 high-flux dialyzer types using a bloodflow of 300 ml/min, dialysate flow 500 ml/min and the dialysis machine Fresenius 5008
Inclusion Criteria:
- ESRD patients 18 years or older
- Stable on hemodialysis for more than 3 months
- An average haematocrit value of 30 % or higher in the last three 3 months
- Stable vascular access of either a fistula or graft
- Stable anticoagulation and regimen
- Stable erythropoiesis-stimulating agent (ESA) regimen for the last three 3 months
- No active infection
- Able to sign informed consent and able to participate in the study
- Medically stable
Exclusion Criteria:
- Participation in another study which may interfere with the planned study
- Active infection
- Medical conditions which may interfere with the study (cardiac, liver disease, hepatitis)
- Female(s) who are pregnant or planning to be pregnant
- Problem with or allergy to anticoagulation
- Central venous catheters
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Dr. Peter Ahrenholz, BioArtProducts GmbH, Rostock, Germany |
| ClinicalTrials.gov Identifier: | NCT01273870 History of Changes |
| Other Study ID Numbers: | PDA-02 |
| Study First Received: | December 22, 2010 |
| Last Updated: | February 1, 2011 |
| Health Authority: | Germany: German Institute of Medical Documentation and Information |
Keywords provided by Praxisverbund Dialyse und Apherese:
|
hemodialysis high-flux-dialyzer performance blood compatibility |
Additional relevant MeSH terms:
|
Kidney Failure, Chronic Renal Insufficiency Renal Insufficiency, Chronic Kidney Diseases Urologic Diseases |
ClinicalTrials.gov processed this record on May 23, 2013